United States Biotechnology & Medical Research

Arcturus Therapeutics Holdings Inc (ARCT)

Track

Recent insider activity at Arcturus Therapeutics involves planned and proposed sales by executives. The most recent transactions occurred on October 15, 2024, when Chief Scientific Officer Pad Chivukula executed divestments. These filings reflect ongoing equity liquidation patterns observed throughout the year, with no reported open-market purchases by company leadership during this period.
Ticker: ARCT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arcturus Therapeutics Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 15 Oct 2024
Value US$961,039.75 | Price 431.18 | Shares 91,598 (+17.5%)
Proposed sale 15 Oct 2024
Value US$2,177,593.94 | Price 244.70 | Shares 73,928
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-16 2024-10-15 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
91,598 +17.5%
431.18
US$961,040 		91,598 +17.5% 431.18 US$961,040
2024-10-15 2024-10-15 PrS Proposed sale
Chivukula Pad

Officer

Officer
73,928
244.70
US$2,177,594 		73,928 244.70 US$2,177,594
2024-06-14 2024-06-12 S Sale
3.0
SASSINE ANDY

Chief Financial Officer

Executive Director
92,478 -25.2%
34.02
US$2,497,755 		92,478 -25.2% 34.02 US$2,497,755
2024-06-12 2024-06-12 PrS Proposed sale
3.0
SASSINE ANDY

Director

Non-Executive Director
50,000
32.03
US$1,601,500 		50,000 32.03 US$1,601,500
2024-06-18 2024-06-10 PrS Proposed sale
3.6
Kummerfeld Keith C

Officer

Officer
2,000
32.00
US$64,000 		2,000 32.00 US$64,000
2024-06-07 2024-06-05 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
114 -0.0%
45.00
US$5,130 		114 -0.0% 45.00 US$5,130
2024-06-05 2024-06-05 PrS Proposed sale
Chivukula Pad

Officer

Officer
37,000
45.00
US$1,665,000 		37,000 45.00 US$1,665,000
2024-06-04 2024-06-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
26,000 -5.5%
40.01
US$1,040,234 		26,000 -5.5% 40.01 US$1,040,234
2024-06-03 2024-06-03 PrS Proposed sale
Chivukula Pad

Officer

Officer
26,000
40.01
US$1,040,234 		26,000 40.01 US$1,040,234
2024-03-27 2024-03-25 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
17,435 -3.6%
35.02
US$610,574 		17,435 -3.6% 35.02 US$610,574
2024-03-21 2024-03-19 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
8,565 -1.7%
35.01
US$299,839 		8,565 -1.7% 35.01 US$299,839
2024-03-19 2024-03-19 PrS Proposed sale
Chivukula Pad

Officer

Officer
26,000
35.00
US$910,000 		26,000 35.00 US$910,000
2023-11-03 2023-11-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
18.72
US$93,602 		5,000 -1.0% 18.72 US$93,602
2023-10-04 2023-10-02 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
25.61
US$128,062 		5,000 -1.0% 25.61 US$128,062
2023-10-02 2023-10-02 PrS Proposed sale
Chivukula Pad

Officer

Officer
15,000
26.00
US$390,000 		15,000 26.00 US$390,000
2023-09-05 2023-09-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
31.45
US$157,264 		5,000 -1.0% 31.45 US$157,264
2023-09-01 2023-09-01 PrS Proposed sale
Chivukula Pad

Officer

Officer
5,000
31.00
US$155,000 		5,000 31.00 US$155,000
2023-08-03 2023-08-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
34.91
US$174,550 		5,000 -1.0% 34.91 US$174,550
2023-08-01 2023-08-01 PrS Proposed sale
Chivukula Pad

Officer

Officer
5,000
35.00
US$175,000 		5,000 35.00 US$175,000
2023-07-18 2023-07-14 PlS Planned sale
3.6
Kummerfeld Keith C

See Remarks

Officer
6,968 -88.0%
35.00
US$243,880 		6,968 -88.0% 35.00 US$243,880
2023-07-18 2023-07-14 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
25,000 -4.6%
35.01
US$875,250 		25,000 -4.6% 35.01 US$875,250
2023-07-14 2023-07-14 PrS Proposed sale
Chivukula Pad

Officer

Officer
25,000
35.01
US$875,336 		25,000 35.01 US$875,336
2023-07-14 2023-07-14 PrS Proposed sale
3.6
KEITH C KUMMERFELD

Officer

Officer
6,968
35.00
US$243,880 		6,968 35.00 US$243,880
2023-07-07 2023-07-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
28.75
US$143,750 		5,000 -0.9% 28.75 US$143,750
2023-06-05 2023-06-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
27.16
US$135,800 		5,000 -0.9% 27.16 US$135,800
2023-05-12 2023-05-11 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
7,925 -1.4%
30.24
US$239,652 		7,925 -1.4% 30.24 US$239,652
2023-05-11 2023-05-11 PrS Proposed sale
Chivukula Pad

Officer

Officer
7,925
30.24
US$239,682 		7,925 30.24 US$239,682
2023-05-12 2023-05-10 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
17,075 -2.9%
30.00
US$512,250 		17,075 -2.9% 30.00 US$512,250
2023-05-10 2023-05-10 PrS Proposed sale
Chivukula Pad

Officer

Officer
17,075
30.00
US$512,287 		17,075 30.00 US$512,287
2023-05-03 2023-05-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
25.93
US$129,650 		5,000 -0.9% 25.93 US$129,650
2023-04-19 2023-04-18 PlS Planned sale
3.6
Kummerfeld Keith C

See Remarks

Officer
6,968 -88.0%
28.18
US$196,358 		6,968 -88.0% 28.18 US$196,358
2023-04-17 2023-04-17 PrS Proposed sale
3.6
KEITH C KUMMERFELD

Officer

Officer
6,968
28.18
US$196,343 		6,968 28.18 US$196,343
2023-04-05 2023-04-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.8%
25.38
US$126,900 		5,000 -0.8% 25.38 US$126,900
2023-03-08 2023-03-06 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.8%
16.07
US$80,350 		5,000 -0.8% 16.07 US$80,350
2022-12-19 2022-12-15 B Purchase
1.9
Marquet Magda
Non-Executive Director
2,222 +9.8%
18.00
US$39,996 		2,222 +9.8% 18.00 US$39,996
2022-11-28 2022-11-23 B Purchase
3.3
Payne Joseph E

President and CEO

Executive Director
5,000 +0.3%
16.51
US$82,550 		5,000 +0.3% 16.51 US$82,550
2022-01-06 2022-01-04 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
8,100 -1.3%
40.00
US$324,000 		8,100 -1.3% 40.00 US$324,000
2021-12-20 2021-12-16 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
3,633 -0.6%
40.00
US$145,328 		3,633 -0.6% 40.00 US$145,328
2021-12-10 2021-12-08 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
6,367 -1.0%
40.00
US$254,680 		6,367 -1.0% 40.00 US$254,680
2021-11-03 2021-11-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.6%
44.41
US$444,100 		10,000 -1.6% 44.41 US$444,100
2021-10-04 2021-10-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.6%
44.36
US$443,600 		10,000 -1.6% 44.36 US$443,600
2021-04-05 2021-04-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
42.95
US$429,500 		10,000 -1.5% 42.95 US$429,500
2021-03-03 2021-03-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
54.23
US$542,300 		10,000 -1.5% 54.23 US$542,300
2021-02-03 2021-02-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
75.31
US$753,100 		10,000 -1.5% 75.31 US$753,100
2021-01-05 2021-01-04 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
46.40
US$464,000 		10,000 -1.4% 46.40 US$464,000
2020-12-10 2020-12-09 S Sale
3.6
Ultragenyx Pharmaceutical Inc.
Non-Executive Director Large shareholder
357,745 -14.0%
94.97
US$33,975,043 		357,745 -14.0% 94.97 US$33,975,043
2020-12-10 2020-12-08 S Sale
3.6
Ultragenyx Pharmaceutical Inc.
Non-Executive Director Large shareholder
442,255 -14.7%
105.54
US$46,675,593 		442,255 -14.7% 105.54 US$46,675,593
2020-12-03 2020-12-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
96.19
US$961,900 		10,000 -1.4% 96.19 US$961,900
2020-11-03 2020-11-02 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
55.28
US$552,800 		10,000 -1.4% 55.28 US$552,800
2020-10-02 2020-10-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
42.83
US$428,300 		10,000 -1.4% 42.83 US$428,300
2020-09-04 2020-09-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
45.16
US$451,600 		10,000 -1.4% 45.16 US$451,600
2020-06-12 2020-06-12 B Purchase
3.6
Kummerfeld Keith C

See Remarks

Officer
450 +90.0%
33.33
US$14,998 		450 +90.0% 33.33 US$14,998
2020-06-10 2020-06-10 B Purchase
3.3
Payne Joseph E

President and CEO

Executive Director
1,000 +0.1%
31.69
US$31,690 		1,000 +0.1% 31.69 US$31,690
2020-06-10 2020-06-10 B Purchase
3.0
SASSINE ANDY

Chief Financial Officer

Executive Director
5,000 +1.9%
29.74
US$148,700 		5,000 +1.9% 29.74 US$148,700
2019-12-09 2019-12-05 B Purchase SASSINE ANDY

Chief Financial Officer

Executive Director
5,649 +2.2%
9.73
US$54,965 		5,649 +2.2% 9.73 US$54,965
2019-12-05 2019-12-03 B Purchase SASSINE ANDY

Chief Financial Officer

Executive Director
10,000 +4.0%
10.00
US$100,000 		10,000 +4.0% 10.00 US$100,000
2019-09-17 2019-09-13 B Purchase
1.9
Marquet Magda
2,300 +11.3%
10.58
US$24,334 		2,300 +11.3% 10.58 US$24,334
2019-09-12 2019-09-12 B Purchase
3.6
Kummerfeld Keith C

See Remarks
500 +inf%
10.69
US$5,347 		500 +inf% 10.69 US$5,347
2019-08-30 2019-08-29 B Purchase Payne Joseph E

President and CEO

Executive Director Large shareholder
5,000 +0.3%
11.22
US$56,100 		5,000 +0.3% 11.22 US$56,100
2019-08-26 2019-08-23 B Purchase SASSINE ANDY

Chief Financial Officer

Officer
10,000 +4.2%
10.90
US$109,000 		10,000 +4.2% 10.90 US$109,000
2019-08-21 2019-08-20 B Purchase FARRELL PETER C Non-Executive Director
4,432 +11.5%
10.85
US$48,087 		4,432 +11.5% 10.85 US$48,087
2019-08-21 2019-08-19 B Purchase FARRELL PETER C Non-Executive Director
4,681 +13.8%
11.02
US$51,585 		4,681 +13.8% 11.02 US$51,585
Explore more

More insider trading research around Arcturus Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America